Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Identification of patients with increased immunological risk among potential kidney recipients in the Polish population.

Moszkowska G, Zielińska H, Zieliński M, Dukat-Mazurek A, Dębska-Ślizień A, Rutkowski B, Lewandowska D, Danielewicz R, Trzonkowski P.

Hum Immunol. 2014 Jul;75(7):650-5. doi: 10.1016/j.humimm.2014.04.012. Epub 2014 Apr 24.

PMID:
24768949
2.

Algorithm to manage highly sensitized kidney transplant recipients in Poland.

Zielińska H, Moszkowska G, Zieliński M, Debska-Ślizień A, Rutkowski B, Trzonkowski P.

Transplant Proc. 2011 Oct;43(8):2903-7. doi: 10.1016/j.transproceed.2011.08.025.

PMID:
21996185
3.
4.

[Anti-HLA antibodies after bone graft and their impact on kidney transplant programs].

Mosconi G, Baraldi O, Fantinati C, Cappuccilli ML, Corsini S, Zanelli P, Bassi A, Buscaroli B, Feliciangeli G, Stefoni S.

G Ital Nefrol. 2009 Mar-Apr;26 Suppl 45:S58-63. Italian.

PMID:
19382096
5.

Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.

Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G.

Transplantation. 2013 Jan 15;95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc.

PMID:
23238534
6.
7.

Specific "intra-allele" and "intra-broad antigen" human leukocyte antigen alloantibodies in kidney graft transplantation.

Muro M, González-Soriano MJ, Salgado G, López R, Boix F, López M, Campillo JA, Martínez P, Botella C, Gimeno L, Minguela A, Alvarez-López MR, Llorente S.

Hum Immunol. 2010 Sep;71(9):857-60. doi: 10.1016/j.humimm.2010.05.018. Epub 2010 May 25.

PMID:
20510320
8.

Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients.

Süsal C, Roelen DL, Fischer G, Campos EF, Gerbase-DeLima M, Hönger G, Schaub S, Lachmann N, Martorell J, Claas F.

Tissue Antigens. 2013 Aug;82(2):83-92. doi: 10.1111/tan.12137. Epub 2013 May 30.

PMID:
23718733
9.

Sensitization and sensitivity: defining the unsensitized patient.

Gebel HM, Bray RA.

Transplantation. 2000 Apr 15;69(7):1370-4.

PMID:
10798756
10.

Influence of test technique on sensitization status of patients on the kidney transplant waiting list.

Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, Süsal C.

Am J Transplant. 2013 Aug;13(8):2075-82. doi: 10.1111/ajt.12332. Epub 2013 Jul 10.

11.

Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates.

Arnold ML, Dechant M, Doxiadis II, Spriewald BM.

Tissue Antigens. 2008 Jul;72(1):60-6. doi: 10.1111/j.1399-0039.2008.01067.x.

PMID:
18588575
12.

Pre- and posttransplant monitoring of alloantibodies by complement-dependent cytotoxicity and luminex methodologies in liver transplantation.

Monteiro F, Rodrigues H, Kalil J, Castro MC, Panajotopoulos N, Paredes M, Massarolo P, Mies S.

Transplant Proc. 2012 Oct;44(8):2411-2. doi: 10.1016/j.transproceed.2012.07.005.

13.

Definition of permissible and immunogenic HLA antigens based on epitope analysis of the HLA specific antibodies produced in sensitized patients.

Papassavas AC, Stavropoulos-Giokas C, Boletis J, Ioannou S, Iniotaki-Theodoraki A, Kostakis A.

Eur J Immunogenet. 2002 Oct;29(5):401-7.

PMID:
12358849
14.

Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.

Caro-Oleas JL, González-Escribano MF, González-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MÁ, Núñez-Roldán A.

Nephrol Dial Transplant. 2012 Mar;27(3):1231-8. doi: 10.1093/ndt/gfr429. Epub 2011 Aug 2.

15.

Detection of donor-specific-antibodies by solid phase assay and its relevance to complement-dependent-lymphocytotoxicity cross-matching in kidney transplantation.

Ho EK, Vasilescu ER, Vlad G, Clynes RA, Ratner LE, Suciu-Foca N.

Hum Immunol. 2014 Jun;75(6):520-3. doi: 10.1016/j.humimm.2014.03.002. Epub 2014 Mar 21.

PMID:
24662417
16.
17.

Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?

Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC.

Transplantation. 2008 Apr 27;85(8):1200-4. doi: 10.1097/TP.0b013e31816b1c37.

PMID:
18431242
18.

Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study.

Minucci PB, Grimaldi V, Casamassimi A, Cacciatore F, Sommese L, Picascia A, Resse M, Sabia C, Russo A, Napoli C.

Exp Clin Transplant. 2011 Dec;9(6):381-6.

19.

Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.

Bosch A, Llorente S, Diaz JA, Salgado G, López M, Boix F, López-Hernández R, González-Soriano MJ, Campillo JA, Moya-Quiles MR, Perez-Lopez N, Minguela A, Jimeno L, Alvarez-López MR, Muro M.

Hum Immunol. 2012 May;73(5):522-5. doi: 10.1016/j.humimm.2012.02.020. Epub 2012 Mar 6.

PMID:
22425738
20.

Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach.

Poli F, Cardillo M, Scalamogna M.

Hum Immunol. 2009 Aug;70(8):631-5. doi: 10.1016/j.humimm.2009.06.006. Epub 2009 Jun 12.

PMID:
19527758
Items per page

Supplemental Content

Write to the Help Desk